Top Banner
Francis Hunter, PhD Mesopharm Therapeutics, Inc.
20
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Francis Hunter, PhD Mesopharm Therapeutics, Inc..

Francis Hunter, PhD

Mesopharm Therapeutics, Inc.

Page 2: Francis Hunter, PhD Mesopharm Therapeutics, Inc..

Entrepreneurship is a Team Sport

Co-Founder, CEO BTech, PhD

Liggins Institute Business Development

Plant & Food Founder & CEO

Lab Trader NZ Fulbright Scholarship

MBA Stanford GSB

Page 3: Francis Hunter, PhD Mesopharm Therapeutics, Inc..

Breast Cancer Startup Challenge

Page 4: Francis Hunter, PhD Mesopharm Therapeutics, Inc..

200 teams 83 universities 4,356 years of experienceVenture capitalists, seasoned entrepreneurs, clinicians

scientists, consultants, life science executives

Breast Cancer Startup Challenge

Page 5: Francis Hunter, PhD Mesopharm Therapeutics, Inc..

Commercial development plan 130 pages Product and R&D strategy Commercialisation and regulatory strategies Market, IP and competition analyses Financial models Operational strategy

Live pitch

Online elevator pitch

Breast Cancer Startup Challenge

Page 6: Francis Hunter, PhD Mesopharm Therapeutics, Inc..

Breast Cancer Startup Challenge

Page 7: Francis Hunter, PhD Mesopharm Therapeutics, Inc..

Breast Cancer Startup Challenge

Page 8: Francis Hunter, PhD Mesopharm Therapeutics, Inc..

Mesopharm Therapeutics, Inc. (DE C-Corp)

Mesopharm Therapeutics NZ Limited

Page 9: Francis Hunter, PhD Mesopharm Therapeutics, Inc..

Armed Antibody Therapeutic

Monoclonal antibody

Highly cytotoxic drugAlpha particle (Actinium-225)

Page 10: Francis Hunter, PhD Mesopharm Therapeutics, Inc..

ADC IND Submissions to the FDA

KadcylaPeak sales US $2–5BGenentech/RocheAdcetris

Peak sales US $1B+Seattle Genetics

Page 11: Francis Hunter, PhD Mesopharm Therapeutics, Inc..

Networking Matters

Page 12: Francis Hunter, PhD Mesopharm Therapeutics, Inc..

ONESTART Accelerator

Page 13: Francis Hunter, PhD Mesopharm Therapeutics, Inc..

Francis Hunter Graeme Fielder

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2015

2003

B.Tech

Ph.D.

MBA (Stanford)

Plant & Food BD

Industry Liaison

Industry Liaison

CEO

Chair

Research Lead

CEO

Chair

Ph.D.

Hons.

B.Sc.

Challenges Lead

Education Lead

Participant

Participant

Judge

Research Fellow

Technical & Entrepreneurial Training

Page 14: Francis Hunter, PhD Mesopharm Therapeutics, Inc..

Experienced Advisors Are Essential

Thorsten Melcher, PhDSenior DirectorJohnson & Johnson Innovation

Thorsten Melcher, MD PhDFounder & CEOLa Jolla Pharmaceuticals

Jeanette Wood, PhDCSOGenkyotex

Jilly Evans, PhDCo-Founder & CSOPharmAkea

Leon Chen, PhD MBAPartnerOrbiMed

Michael Kolodziej, MDNational Oncology DirectorAetna

Tom John, MBBS PhDHead of Thoracic OncologyAustin Hospital

Page 15: Francis Hunter, PhD Mesopharm Therapeutics, Inc..

NZ, US, AusR&D

Best-in-classtherapeutics

Management& advisory

strength

Page 16: Francis Hunter, PhD Mesopharm Therapeutics, Inc..

Enter the Spark Challenge!

Page 17: Francis Hunter, PhD Mesopharm Therapeutics, Inc..

In-Licensing Technology

Leverage

Page 18: Francis Hunter, PhD Mesopharm Therapeutics, Inc..

Starting Up by Licensing

ibridgenetwork.org – 18,000 patents 15,000 new patents filed by US universities

in FY2013

Page 19: Francis Hunter, PhD Mesopharm Therapeutics, Inc..

Starting Up by Licensing: Playbook

Define a PROBLEM (=MARKET) RESEARCH the problem and possible solutions Identify technology PATENTS Choose your top 5 and become a

TERRIBLE EXPERT Approach the inventors and licensing

institution Select your best tech: Impact and maturity Build your TEAM, then LICENSE

Page 20: Francis Hunter, PhD Mesopharm Therapeutics, Inc..

[email protected]

@TumourKiller